Biotechnology development (+CILS)

Mon 25.03.2019, 10:30-12:00 CMU, room A04.2910; Tue 26.03.2019, 08:30-09:15 CMU, room A04.2910; Tue 26.03.2019, 09:15-10:00 CMU, room A04.2910; Tue 26.03.2019, 10:30-11:15 CMU, room A04.2910;Tue 26.03, 11:30-12:15 CMU, room A04.2910 Mon 08.04.2019, 08:30-10:00 CMU, room A04.2711; Mon 08.04.2019, 10:30-12:00 CMU, room A04.2711; Mon 08.04.2019, 13:30-15:00 CMU, room A04.2711; Tue 09.04.2019, 13:00-14:00 CMU, room B04.1520; Tue 09.04.2019, 14:30-16:00 CMU, room B04.1520; Mon 06.05.2019, 09:30-11:00 CMU, room B04.1520

Yogeshvar Kalia

Dr Walter FERLIN, Novimmune

NovImmune collaborators:

Dr Amanda PROUDFOOT

Dr Emmanuel MONNET

Dr Nicolas FISCHER

Giovanni MAGISTRELLI 

Dr Adrian HAINES

Dr Vanessa BUATOIS

Dr Laetitia SORDE

Dr Hasnaà HADDOUK

Dr Robert NELSON

Dr Krzysztof MASTERNAK

Dr Walter FERLIN

Course Outline:

· Overview of the steps for drug development (2h, EM)

· Therapeutic antibody formats and discovery platforms (2h, NF)

· Toolbox to streamline the identification of Antibody Drug Candidate (1h, GM)

· Manufacturing antibodies (1h, AH)

· Preclinical drug development: in vitro and in vivo pharmacology (2h, VB)

· Introduction to bioanalysis and clinical sample testing (1h, RN)

· Immunogenicity of biotherapeutics (1h, LS)

· Non-Clinical Safety Requirements before First in Human (2h, HH)

· Harnessing innate and adaptive anticancer immunity with anti-CD47 antibodies (2h, KM)

· Title to be determined (1h, AP)

· Bringing an antibody program from a concept to patients (2h, WF)

Genève, CMU

10